國內最新研究發現，中度肝纖維化致肝癌風險為 6.55倍。不過，目前國內針對 C肝全口服新藥的健保給付條件中，僅納入重度纖維化 C肝患者。專家呼籲，政府應將給付條件放寬至中度肝纖維化患者，積極降低肝癌風險。
台灣肝臟研究學會暨肝病醫療策進會長、台大講座教授高嘉宏指出，肝臟是沉默的器官，若反覆發炎細胞持續損傷，在歷經結疤又修復過程後，肝臟內結締組織會增多並逐漸變硬，這個過程即所謂的肝纖維化。肝纖維化可分為 0-4期，第 0期是無纖維化，第 1期是輕度纖維化，第 2期是中度，第 3期則為重度，到了第 4期就已達肝硬化階段。
高雄醫學大學附設中和紀念醫院肝膽胰內科暨高雄醫學大學特聘教授余明隆說，若有肝纖維化，肝癌風險相對就會增加。依據高雄醫學大學附設中和紀念醫院在追蹤高醫與其他 3家區域醫院、共 1281名 C肝患者長達 5年多發現，年齡 40歲以上者與中度肝纖維化，都是增加肝癌風險的重要危險因子。
另外，余明隆指出，根據國內的醫療研究資料顯示，相較於輕度纖維化已治癒患者，中度肝纖維化未治癒患者罹患肝癌的風險機率為 6.55倍；未治癒中度肝纖維化患者相較於無纖維化、輕度纖維化患者，其罹患肝癌的風險機率為 3.7倍；未治癒之輕度肝纖維化若惡化為中度纖維化時，罹患肝癌的機率會提升 2.7倍。
目前政府針對 C肝全口服新藥的健保給付條件中，僅納入重度纖維化 C肝患者。高嘉宏呼籲，政府應於下半年度放寬至中度纖維化患者，並提倡民眾應主動掌握肝臟纖維化狀況，有纖維化就應積極與醫師溝通追蹤與治療計畫。
為讓民眾方便計算自己的肝纖維化指數，肝策會提供國內第一個中文介面的「肝纖維化指數」應用程式 APP。民眾搜尋「 HCVie」即可免費下載。只要從抽血報告中，將血小板、肝功能指數 ALT(GPT)、 AST(GOT)及年齡 4個數值帶入公式中即可計算。若是無或輕微肝纖維化，會顯示綠燈；若是中度以上，呈現黃、橘、紅等不同燈號，應盡快就醫檢查。
The latest domestic research found that the risk of liver cancer caused by moderate liver fibrosis was 6.55 times. However, at present, only the patients with severe fibrosis C liver disease are included in the health insurance payment conditions for the new oral administration of C liver. Experts have called for the government to relax the conditions for patients with moderate liver fibrosis and actively reduce the risk of liver cancer.
Gao Jiahong, president of Taiwan Liver Research Society and Hepatology Medical Policy, and lecturer of Taiwan University, Gao Jiahong pointed out that the liver is a silent organ. If the inflamed cells continue to be damaged, the connective tissue in the liver will increase and gradually harden after the process of crusting and repairing. This process is called liver fibrosis. Liver fibrosis can be divided into 0-4, the first phase is no fibrosis, the first phase is mild fibrosis, the second phase is moderate, the third phase is severe, and the fourth phase has reached the liver. Hardening stage.
Yu Minglong, a professor of the Department of Hepatobiliary and Pancreatic Medicine of Kaohsiung Medical University and Kaohsiung Medical University, said that if there is liver fibrosis, the risk of liver cancer will increase. According to the Zhonghe Memorial Hospital attached to Kaohsiung Medical University, a total of 1281 patients with C liver were followed up for more than 5 years. The patients over 40 years old and moderate liver fibrosis were all at increased risk of liver cancer. Important risk factor.
In addition, Yu Minglong pointed out that according to domestic medical research data, the risk of liver cancer in patients with moderate hepatic fibrosis was 6.55 times higher than that in patients with mild fibrosis; untreated patients with moderate hepatic fibrosis In patients with no fibrosis and mild fibrosis, the risk of developing liver cancer is 3.7 times; if the unhealed mild liver fibrosis deteriorates to moderate fibrosis, the chance of developing liver cancer will increase by 2.7 times.
At present, the government only includes severe fibrotic C liver patients for the health insurance payment conditions for C-hepatic oral new drugs. Gao Jiahong called for the government to relax to moderately fibrotic patients in the second half of the year and advocate that people should take the initiative to master the liver fibrosis. If there is fibrosis, they should actively communicate with the physicians to track and treat the treatment.
In order to make it easier for the public to calculate their liver fibrosis index, the liver policy will provide the first Chinese language interface for the "fibrosis index" app. People search for "HCVie" for free download. As long as the blood pumping report, the platelet, liver function index ALT (GPT), AST (GOT) and age values ??are taken into the formula to calculate. If there is no or slight liver fibrosis, it will display a green light; if it is moderate or above, it will display different signs such as yellow, orange and red, and should be examined as soon as possible.
laennec is the ethical drug manufactured with JBP’s unique technologies.
Laennec is the ethical drug manufactured with JBP’s unique technologies for effective extraction of variety of growth factors, cytokines, and other physiologically active substances from the human placenta. For instance, HGF (hepatocyte growth factor) promotes the proliferation of hepatic parenchymal cells for recovery of a damaged liver. Our product safety is ensured by the most rigid safety measures among existing scientific standards.
留言列表
